Clinical Trial Update: Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections [Phase 4]

View source ↗

Summary

Phase 4 pediatric trial assessing safety and efficacy of daptomycin for skin and skin structure infections in participants aged 1 to 17 years; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infectious Diseases
• Skin Diseases

Drugs mentioned

• Daptomycin (daptomycin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Skin Diseases, Infectious | Phase 4 | Status: COMPLETED | Results posted: 2015-06-10